Compare CPSH & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPSH | ENTX |
|---|---|---|
| Founded | 1984 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.9M | 58.2M |
| IPO Year | 1995 | 2015 |
| Metric | CPSH | ENTX |
|---|---|---|
| Price | $5.21 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $9.00 |
| AVG Volume (30 Days) | 1.8M | ★ 3.0M |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 113.64 | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | $16.41 | N/A |
| Revenue Next Year | $20.16 | N/A |
| P/E Ratio | ★ N/A | $23.71 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.11 | $0.91 |
| 52 Week High | $14.39 | $3.22 |
| Indicator | CPSH | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 65.97 |
| Support Level | $4.61 | $1.45 |
| Resistance Level | $5.50 | $1.94 |
| Average True Range (ATR) | 0.68 | 0.27 |
| MACD | -0.21 | 0.04 |
| Stochastic Oscillator | 9.97 | 32.10 |
CPS Technologies Corp designs, manufactures, and sells high-performance material solutions for customers across various markets, including transportation, energy, automotive, electronics, telecommunications, aerospace, and defense. The company develops and applies proprietary expertise in metal matrix composites (MMCs), which are engineered materials combining metals and ceramics to achieve enhanced performance properties. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers. The majority of the company's revenue is derived from the sale of its products in the United States of America.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.